| 000 | 01778 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513210414.0 | ||
| 264 | 0 | _c20000606 | |
| 008 | 200006s 0 0 eng d | ||
| 022 | _a0090-8258 | ||
| 024 | 7 |
_a10.1006/gyno.2000.5728 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKonecny, G | |
| 245 | 0 | 0 |
_aCorrelation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. _h[electronic resource] |
| 260 |
_bGynecologic oncology _cMay 2000 |
||
| 300 |
_a258-63 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenosine Triphosphate _xblood |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aCarboplatin _xpharmacology |
| 650 | 0 | 4 |
_aCarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aCisplatin _xpharmacology |
| 650 | 0 | 4 |
_aCyclophosphamide _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 |
_aEpirubicin _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPaclitaxel _xpharmacology |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aRegression Analysis |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aCrohns, C | |
| 700 | 1 | _aPegram, M | |
| 700 | 1 | _aFelber, M | |
| 700 | 1 | _aLude, S | |
| 700 | 1 | _aKurbacher, C | |
| 700 | 1 | _aCree, I A | |
| 700 | 1 | _aHepp, H | |
| 700 | 1 | _aUntch, M | |
| 773 | 0 |
_tGynecologic oncology _gvol. 77 _gno. 2 _gp. 258-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1006/gyno.2000.5728 _zAvailable from publisher's website |
| 999 |
_c10737822 _d10737822 |
||